TRIP13 - - 癌症药物治疗中的潜在药物标
Samuel Jacob Bunu1, Haiyan Cai2, Leyun Wu1
1State Key Laboratory of Drug Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; School of Pharmacy, University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, China.
甲状腺激素受体相互作用蛋白-13 (TRIP13) 是一个AAA+ATPase和瘤基因. 这篇评论详细介绍了TRIP13的细节.
科学领域:
- 分子生物学分子生物学
- 生物化学 生物化学
- 在瘤学瘤学.
背景情况:
- 与多种细胞活动相关的ATPases (AAA+ATPases) 是人类细胞中关键的酶蛋白.
- 甲状腺激素受体相互作用蛋白-13 (TRIP13) 是一个AAA+ATPase,涉及DNA修复和分裂.
- TRIP13在各种人类恶性瘤中起着瘤基因的作用,包括脑瘤和多发性髓瘤.
研究的目的:
- 提供TRIP13在癌症中的生物学功能,结构和作用的全面审查.
- 探索TRIP13活动及其相互作用的分子机制,例如与MAD2.
- 讨论TRIP13作为抗癌药物标的潜力,包括已知的小分子抑制剂.
主要方法:
- 对有关TRIP13的现有文献进行系统审查.
- 对TRIP13的蛋白质结构和ATP结合机制的分析.
- 关于TRIP13在18种不同类型癌症中的影响的数据汇编.
主要成果:
- TRIP13的结构阐明了它的ATP结合和MAD2识别机制,p31作为适配器.
- TRIP13与至少18种人类癌症的进展有关.
- 四种小分子抑制剂 (DCZ0415,TI17,DCZ5417,DCZ5418) 显示出显著的TRIP13抑制和抑制癌细胞.
结论:
- 由于其致癌功能,TRIP13是一种经过验证和重要的抗癌药物标.
- 针对TRIP13的小分子抑制剂在癌症治疗中显示出前景.
- 对TRIP13的机制和抑制剂的进一步研究可能会导致新的治疗策略.
更多相关视频
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Stabilize Microtubules
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity
